- Home
- Solutions
- By Diseases
- Congenital Ophthalmic Diseases
- Congenital Fibrosis of the Extraocular Muscles
Congenital Fibrosis of the Extraocular Muscles (CFEOM) is a highly distinctive genetic disorder that falls under the category of congenital cranial dysinnervation disorders (CCDDs). With rich experience and a top-notch team, Protheragen is well-positioned to provide customized CFEOM diagnostics and therapy development solutions.
Congenital Fibrosis of the Extraocular Muscles (CFEOM) is a group of rare genetic disorders characterized by nonprogressive restrictive ophthalmoplegia, leading to severe limitations in eye movement. These conditions are part of the congenital cranial dysinnervation disorders (CCDDs), affecting the development of cranial nerves and their nuclei. CFEOM presents with significant phenotypic and genotypic heterogeneity, with at least five subtypes (CFEOM-1 to CFEOM-5), each associated with distinct genetic mutations and features.
Fig.1 Schematic representation of the KIF21A protein structure. (Trejo-Reveles V., et al., 2023)Genetic testing has revolutionized the diagnosis of CFEOM by identifying causative genes and mutations. With at least seven causative genes identified, including KIF21A, PHOX2A, TUBB3, TUBB2B, TUBA1A, ECEL1, and COL25A1, genetic testing is now a cornerstone in the diagnostic process. For example, mutations in the KIF21A gene are the most common cause of CFEOM, accounting for over half of all cases and are associated with CFEOM-1 and a small proportion of CFEOM-3 cases.
Targeting Genetic Mutations
The advent of gene therapy offers promising avenues for addressing the genetic etiologies of CFEOM. By utilizing advanced techniques such as CRISPR/Cas9 gene editing, the potential to correct or mitigate the underlying genetic defects is being increasingly realized. For instance, gene therapies targeting mutations in KIF21A, notable for their role in CFEOM-1, open up possibilities for restoring normal function to aberrant cranial nerves. Such therapeutic strategies are at the forefront of scientific exploration, aimed at not just alleviating symptoms but targeting the root genetic cause.
Challenges and Opportunities in Gene Therapy
The promise of gene therapy is tempered by significant hurdles, primarily concerning accuracy, effectiveness, and security. Optimal design of delivery systems, like viral vectors, is crucial for achieving tissue-specific gene expression, minimizing off-target impacts, and maintaining long-term therapeutic efficacy. These challenges present an opportunity for extensive research and innovation, holding the potential for significant advances in the therapeutic development of complex conditions.
As a research services provider, Protheragen is committed to providing one-stop CFEOM diagnostics and therapeutic development services. Our expertise lies in exploring the genetic architecture of CFEOM to unearth novel therapeutic targets, leveraging cutting-edge technology to propel drug discovery and gene therapy development.
We help pinpoint and validate novel therapeutic targets for congenital fibrosis of the extraocular muscles (CFEOM). Our approach combines multi-omics profiling—genomics, transcriptomics, and single-cell RNA sequencing—of disease-relevant tissues and cell models to uncover dysregulated pathways linked to KIF21A, PHOX2A, TUBB3, and other CFEOM-associated mutations. Functional validation is performed using both in vitro systems (human extraocular muscle cells, orbital fibroblasts, cranial nerve cells) and in vivo models to confirm target involvement in EOM fibrosis and cranial nerve dysfunction.
Accurate disease models are essential for advancing CFEOM therapeutics. We develop and characterize physiologically relevant systems that replicate key disease features: restrictive strabismus, ptosis, EOM fibrosis, and aberrant cranial nerve innervation. Our capabilities span patient-derived iPSC differentiation into extraocular muscle cells, orbital fibroblasts, and cranial nerve cells; 3D EOM organoids; and genetically engineered animal models including KIF21A knockout mice and TUBB3 mutant zebrafish.
We rigorously assess candidate therapies across modalities—small molecules, gene therapies, biologics, and anti-fibrotic agents—using validated preclinical models. Our efficacy evaluations focus on clinically meaningful endpoints: TGF-β pathway modulation, reduction of fibrotic burden, restoration of muscle function, and promotion of axonal outgrowth in cranial nerve populations.
Given CFEOM's pediatric population and potential long-term treatment requirements, we conduct GLP-compliant safety evaluations with emphasis on ocular, neuromuscular, and systemic toxicology. Our battery includes cytotoxicity, genotoxicity, and hemocompatibility assays using primary human ocular and neuromuscular cells to ensure candidate safety at the cellular level.
Protheragen's preclinical research services are dedicated to advancing the understanding of CFEOM at the molecular and cellular levels. Our services include:
If you are interested in our services, please feel free to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.
